Scholar Rock Holding (FRA:2QK) 3-Month Share Buyback Ratio: -2.10% (As of Jun. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2QK Scholar Rock Holding Corp FRA:2QK
34 GF Score
Price €47.10
GF Value €25.26
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Scholar Rock Holding 3-Month Share Buyback Ratio?

Scholar Rock Holding FRA:2QK -0.78% 34 3-Month Share Buyback Ratio is -2.10 as of Jun. 2026. GuruFocus rates FRA:2QK with a GF Score™ of 34/100 and a GF Value™ of €25.26 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Scholar Rock Holding's current 3-Month Share Buyback Ratio was -2.10%.


Scholar Rock Holding  (FRA:2QK) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Scholar Rock Holding 3-Month Share Buyback Ratio Related Terms


FRA:2QK vs CAI, RYTM, CGON: 3-Month Share Buyback Ratio Comparison

For the Biotechnology subindustry, Scholar Rock Holding's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scholar Rock Holding 3-Month Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Scholar Rock Holding's 3-Month Share Buyback Ratio falls into.


FRA:2QK
34GF Score
Scholar Rock Holding Corp FRA:2QK
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scholar Rock Holding 3-Month Share Buyback Ratio Calculation

Scholar Rock Holding's 3-Month Share Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Mar. 2026 ) - Shares Outstanding (EOP) (Jun. 2026 )) / Shares Outstanding (EOP) (Mar. 2026 )
=(119.104 - 121.600) / 119.104
=-2.10%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of -2.10 mean?
Scholar Rock Holding (FRA:2QK) has a 3-Month Share Buyback Ratio of -2.10 as of Jun. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Scholar Rock Holding and its competitors.
Is Scholar Rock Holding's 3-Month Share Buyback Ratio too high?
Scholar Rock Holding's current 3-Month Share Buyback Ratio is -2.10. Overall, Scholar Rock Holding has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's 3-Month Share Buyback Ratio compare to CAI and RYTM?
Scholar Rock Holding's 3-Month Share Buyback Ratio of -2.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Scholar Rock Holding and its competitors. Scholar Rock Holding's current 3-Month Share Buyback Ratio is -2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Based on GuruFocus' analysis, Scholar Rock Holding (FRA:2QK) is currently considered Significantly Overvalued. The stock's GF Value™ is €25.26, compared to a current price of €47.10 — trading 86.5% above its estimated fair value. The current 3-Month Share Buyback Ratio is -2.10. Scholar Rock Holding's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current 3-Month Share Buyback Ratio is -2.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scholar Rock Holding (FRA:2QK) Overvalued in 2026?

Based on GuruFocus' analysis, Scholar Rock Holding stock appears to be overvalued. The current stock price of €47.10 is trading 86.5% above its estimated GF Value™ of €25.26. GuruFocus considers Scholar Rock Holding to be Significantly Overvalued.

Key valuation signals for FRA:2QK:

  • 3-Month Share Buyback Ratio: -2.10
  • GF Value™: €25.26 vs. price of €47.10 (86.5% above fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the FRA:2QK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scholar Rock Holding Business Description

Other Exchanges SRRK:USA2QK:Germany
Address 301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
34GF Score

Get the complete analysis for FRA:2QK

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.10
Price
€25.26
GF Value